The prognostic effect of immunoscore in patients with clear cell renal cell carcinoma: preliminary results
- 71 Downloads
This study aimed to evaluate the density of CD8+ and CD3+ tumor-infiltrating lymphocytes (TILs) and determine whether the immunoscore has any prognostic effect on the oncological outcomes in patients with clear cell renal cell carcinoma (RCC).
Materials and methods
A total of 129 patients diagnosed with clear cell RCC following radical or partial nephrectomy between 2009 and 2014 were retrospectively analyzed. Both tumor core (CT) and the invasive margin of nephrectomy specimens were assessed. The specimens were immunostained for anti-CD8+ and anti-CD3+ TILs. The patients were divided into three groups (favorable, intermediate, and poor risk) according to immunoscore levels.
In the multivariate analysis, a favorable immunoscore (I3–4) was associated with prolonged disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) (HR 2.652, 2.848, and 2.933, respectively; all p < 0.001). The lower Fuhrman grade and pathological tumor-node-metastasis (TNM) stage had better DFS, PFS, and OS, whereas prolonged PFS was associated with a higher density of CD8+ CT (HR 1.602, 95% CI 0.934–3.470; p = 0.014). The shorter DFS, PFS, and OS were observed in the group with poor immunoscore (I0–1) at the early TNM stage of RCC (p < 0.001). In the metastatic subgroup analysis, the immunoscore showed better estimation than the International Metastatic RCC Database Consortium model and the Memorial Sloan-Kettering Cancer Center risk model for progression and OS (p < 0.001).
The additional contributions of immunoscore to TNM stage, Fuhrman grade, and the WHO/ISUP 2016 grade for estimating oncological outcomes were found in ROC analysis. According to our preliminary results, immunoscore can be a promising prediction tool in clear cell RCC for postoperative oncological outcomes following nephrectomy.
KeywordsCD3+ CD8+ Clear cell renal cell carcinoma Immunoscore Oncologic outcomes Tumor-infiltrating lymphocytes
IS: conception and design, acquisition of data, statistical analysis, analysis and interpretation of data, and drafting of the manuscript. UD: conception and design, and critical revision of the manuscript for important intellectual content. NB: analysis and interpretation of data, pathological evaluation, and critical revision of the manuscript for important intellectual content. HB: critical revision of the manuscript for important intellectual content.
This work is financially supported by Health Science University Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital through the scientific research fund with the decision of dated 03.11.2017 and numbered 1.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval for research involving human participants
The study was approved by the local ethics committee (the protocol number: 2018-02/18; the date of approval: February 7, 2018) at Health Science University Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. All procedures performed in our study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informal written informed consent was obtained from all individual participants included in the study. The data of patients who did not consent were not used.
- 3.Ljungberg B, Albiges L, Bensalah K et al (2019) European Association of Urology guidelines on renal cell carcinoma: the 2019 update. In. ISBN 978-94-92671-04-2. EAU Guidelines Office, Arnhem, The Netherlands. ISBN 978-94-92671-04-2. http://uroweb.org/guidelines/compilations-of-all-guidelines/. Accessed 19 Mar 2019
- 6.Kim JK, Kim SH, Song MK, Joo J, Seo SI, Kwak C et al (2019) Application of the international metastatic renal cell carcinoma database consortium and memorial Sloan Kettering cancer center risk models in patients with metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study using the korean metastatic renal cell carcinoma registry. Cancer Res Treat 51(2):758–768CrossRefGoogle Scholar
- 12.Rabjerg M (2017) Identification and validation of novel prognostic markers in renal cell carcinoma. Dan Med J 64(10):B5339Google Scholar
- 16.Ingels A, Salas RES, Ravery V, Fromont-Hankard G, Validire P, Patard JJ et al (2014) T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: proof of concept. Ecancer Med Sci 8:486Google Scholar
- 19.Yu A, Mansure JJ, Solanki S, Siemens DR, Koti M, Dias ABT et al (2018) Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+ , CD8+ , and immunoscore as prognostic marker in patients after radical cystectomy. PLoS One 13(10):e0205746. https://doi.org/10.1371/journal.pone.0205746.eCollection2018 CrossRefGoogle Scholar
- 21.Sun C, Xu J, Song J, Liu CQ, Wang J, Weng C et al (2015) The predictive value of centre tumour CD8+ T cells in patients with hepatocellular carcinoma: comparison with immunoscore. Oncotarget 34:35602–35615Google Scholar
- 27.Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER). NCT03055013. https://clinicaltrials.gov/ct2/home. Accessed 24 May 2017
- 28.A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010). NCT03024996 Available at:https://clinicaltrials.gov/ct2/home. Accessed 24 May 2017